Cryoport (NASDAQ:CYRX) Price Target Raised to $11.00

Cryoport (NASDAQ:CYRX - Get Free Report) had its price target hoisted by analysts at UBS Group from $10.00 to $11.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock. UBS Group's price objective would indicate a potential upside of 105.99% from the stock's current price.

Other research analysts have also issued research reports about the stock. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a research note on Monday, March 31st. Guggenheim assumed coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, Cryoport has an average rating of "Moderate Buy" and an average target price of $11.83.

Cryoport Trading Down 1.8 %

NASDAQ CYRX traded down $0.10 on Tuesday, reaching $5.34. The stock had a trading volume of 711,745 shares, compared to its average volume of 537,736. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The stock has a fifty day moving average price of $6.45 and a two-hundred day moving average price of $7.24. Cryoport has a 12-month low of $4.58 and a 12-month high of $19.00. The firm has a market capitalization of $266.52 million, a price-to-earnings ratio of -1.58 and a beta of 1.67.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $59.53 million during the quarter, compared to analysts' expectations of $58.71 million. During the same quarter in the prior year, the firm posted ($0.29) EPS. As a group, sell-side analysts forecast that Cryoport will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jerrell Shelton sold 4,620 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 19,830 shares of company stock worth $118,353 over the last 90 days. 10.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Cryoport

Large investors have recently bought and sold shares of the business. Bullseye Asset Management LLC lifted its stake in Cryoport by 58.7% during the third quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company's stock worth $1,737,000 after purchasing an additional 79,244 shares during the last quarter. Barclays PLC boosted its holdings in shares of Cryoport by 272.9% in the 3rd quarter. Barclays PLC now owns 81,417 shares of the company's stock valued at $660,000 after buying an additional 59,582 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Cryoport in the 3rd quarter valued at $3,405,000. SG Americas Securities LLC raised its stake in Cryoport by 44.8% during the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company's stock worth $1,142,000 after acquiring an additional 45,430 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in Cryoport by 2.9% in the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after acquiring an additional 1,764 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.